CareLit · DOI-Nachweis · Aktuelle Neurologie
TGF-beta2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: safety and efficacy results of phase I/II clinical studies
DOI 10.1055/s-2004-832961
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Hau, U Bogdahn, A Brawanski, D Freudenstein, M Goldbrunner, W Grisold, T Hundsberger, D Koch, H Kostron, M Kunst, M Mehdorn, J Meixensberger, J Pichler, G Schackert, J Schlaier, R Schlingensiepen, S Schmaus, T Schneider, L Spitznagel, G Stauder, G Stockhammer, H Wassmann, M Weller, M Winking, G W…
ZeitschriftAktuelle Neurologie
Ausgabe09/2004
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Tumor derived transforming growth factor beta (TGF-beta) is a pivotal factor for malignant progression by inducing metastasis, angiogenesis, tumor cell proliferation and immunosuppression. High-grade gliomas are highly aggressive tumors showing marked overexpression of the TGF-beta2 isoform which is correlated with advanced tumor stage. Methods: In 3 phase I/II dose escalation studies adult high-grade gl…
Zitieren
Zitierempfehlung
P Hau, U Bogdahn, A Brawanski, D Freudenstein, M Goldbrunner, W Grisold, T Hundsberger, D Koch, H Kostron, M Kunst, M Mehdorn, J Meixensberger, J Pichler, G Schackert, J Schlaier, R Schlingensiepen, S Schmaus, T Schneider, L Spitznagel, G Stauder, G Stockhamm… (2004) TGF-beta2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: safety and efficacy results of phase I/II clinical studies. Aktuelle Neurologie (09). https://doi.org/10.1055/s-2004-832961
Mit CareLit weiterarbeiten